Application of prevotella in preparation of medicine for treating cholestatic diseases

Abstract

The invention discloses application of prevotella in preparation of a medicine for treating cholestatic diseases. The cholestatic diseases include, but is not limited to, primary sclerosing cholangitis. After the inventor constructs a PSC animal model, it is determined that the abundance of P.copri in mice is consistently reduced in the same population, then intervention effects of P.copri on inflammation, fibrosis, cholestasis and the like of the PSC model are observed and evaluated through intragastric administration for one week and daily supplementation of 1*10<8> CFU of P.copri bacterial liquid, bile acid metabolism changes are determined through total bile acid determination and targeted bile acid detection analysis, and the action mechanism is analyzed. Experiments prove that the P.copri can obviously relieve cholestasis in hepatointestinal circulation of PSC mice and obviously improve liver fibrosis, which is of great significance to prevention or treatment of cholestatic diseases.

Description

technical field [0001] The invention belongs to the technical field of biomedicine, and in particular relates to the application of Prevotella in the preparation of medicines for treating cholestasis diseases. Background technique [0002] Cholestasis disease is a kind of disease of bile synthesis, metabolism and excretion disorder, which will cause a large amount of bile components such as bile acid to accumulate in the liver and flow back into the blood, thus causing organic damage, metabolic disorder and dysfunction in the hepatobiliary system Clinically, patients will be accompanied by jaundice, pruritus, and elevated serum alkaline phosphatase. Primary sclerosing cholangitis (PSC) is a chronic cholestatic disease characterized by progressive inflammation and fibrosis of intrahepatic and extrahepatic bile ducts and multifocal biliary strictures. Clinically, PSC remains a rare disease of unknown etiology with a poor prognosis, and most patients can develop cirrhosis, por...

AI Technical Summary

Problems solved by technology

[0003] At present, ursodeoxycholic acid (ursodesoxycholic aci, UDCA) is the drug of choice in the clinical treatment of this disease, but it can only improve cholestasis for some patients in the early stage, but the effect on patients in the middle and late stage is limited

In addition, some traditional Chinese medicines, such as astr

Images